Thc Therapeutics Stock Last Dividend Paid
THCT Stock | USD 0.0007 0.00 0.00% |
THC Therapeutics fundamentals help investors to digest information that contributes to THC Therapeutics' financial success or failures. It also enables traders to predict the movement of THC Pink Sheet. The fundamental analysis module provides a way to measure THC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to THC Therapeutics pink sheet.
THC |
THC Therapeutics Company Last Dividend Paid Analysis
THC Therapeutics' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Competition |
Based on the recorded statements, THC Therapeutics has a Last Dividend Paid of 0.0. This indicator is about the same for the Health Care Equipment & Supplies average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Analyzer Now
Portfolio AnalyzerPortfolio analysis module that provides access to portfolio diagnostics and optimization engine |
All Next | Launch Module |
THC Fundamentals
Return On Asset | -5.57 | |||
Current Valuation | 1.57 M | |||
Shares Outstanding | 34.15 M | |||
Shares Owned By Insiders | 30.84 % | |||
Price To Earning | 1.25 X | |||
Price To Book | 46.07 X | |||
EBITDA | (1.06 M) | |||
Net Income | (1.89 M) | |||
Cash And Equivalents | 3.82 K | |||
Total Debt | 925.89 K | |||
Debt To Equity | 18.70 % | |||
Current Ratio | 0.01 X | |||
Book Value Per Share | (0.15) X | |||
Cash Flow From Operations | (388.48 K) | |||
Earnings Per Share | (0.09) X | |||
Beta | 1.71 | |||
Market Capitalization | 1.09 M | |||
Total Asset | 480.07 K | |||
Z Score | -6.0 | |||
Net Asset | 480.07 K |
About THC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze THC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of THC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of THC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for THC Pink Sheet Analysis
When running THC Therapeutics' price analysis, check to measure THC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Therapeutics is operating at the current time. Most of THC Therapeutics' value examination focuses on studying past and present price action to predict the probability of THC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Therapeutics' price. Additionally, you may evaluate how the addition of THC Therapeutics to your portfolios can decrease your overall portfolio volatility.